Novel biologics in treatment of psoriatic arthritis.
- Author:
Jiong ZHOU
1
;
Min ZHENG
Author Information
1. Department of Dermatology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China.
- Publication Type:Journal Article
- MeSH:
Adalimumab;
Anti-Inflammatory Agents, Non-Steroidal;
therapeutic use;
Antibodies, Monoclonal;
therapeutic use;
Antibodies, Monoclonal, Humanized;
Arthritis, Psoriatic;
drug therapy;
etiology;
Dermatologic Agents;
therapeutic use;
Etanercept;
Humans;
Immunoglobulin G;
therapeutic use;
Receptors, Tumor Necrosis Factor;
therapeutic use;
Recombinant Fusion Proteins;
therapeutic use
- From:
Journal of Zhejiang University. Medical sciences
2009;38(4):404-408
- CountryChina
- Language:Chinese
-
Abstract:
Psoriatic arthritis is an inflammatory joint disease associated with psoriasis. Due to difficulty for early diagnosis and lack of effective therapy, the disease leads to chronic course and frequent relapse. Patients may suffer from ankylosis,disability and even death. The past treatments neither can control the disease effectively, nor be capable of inhibiting the development of structural joint damage. Based on the current psoriasis pathogenesis, novel biologics have been developed,which can aim the specific targets, resulting in more effective and safer management for psoriatic arthritis.
